Personalized Therapies in Inflammatory Complex Disease (PIMOC)

Personalized Targeted Therapies in Inflammatory Complex Multi Organ Disease

Inflammatory diseases may display atypical features making such patients impossible to classify. Management of these cases in daily practice cannot rely on the results of clinical trials nor on guidelines. DNA and RNA mapping have become major tools to understand and sometimes direct the treatment strategy in oncology. This study aims to test whether a precise analysis of molecular pathways in inflammatory, non classified diseases, can constitute a predictive tool of therapeutic efficiency

Study Overview

• Status: Completed
• Conditions: Autoimmune Diseases; Inflammatory Disease
• Intervention / Treatment: Drug: Kineret; Drug: Humira; Drug: Stelara; Drug: Cosentyx; Drug: Roactemra; Drug: Rituximab

Detailed Description

This is a phase IIb study. The main objective of this study is to evaluate the efficacy of targeted treatments in patients displaying a non-classified, severe and resistant inflammatory disease. Targeted treatments for each patient will have been selected through an algorithm based on molecular analysis of specific altered inflammatory signaling pathway.

Treatments consist in targeted therapies approved in other indications (Kineret®, Humira®, Stelara®, Cosentyx®, Roactemra® and Rituximab®) that will be given once selected using molecular analysis and decision making procedure by the Scientific committee.

For each patient, one targeted treatment will be administered according to the SmPC procedure for a treatment period of 6 months.

Primary efficacy endpoint:

Response will be assessed at month 6 with a composite endpoint defined as improvement of at least 2 of the 3 following parameters:

• 50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10 mm),
• and/or 50% improvement of cutaneous activity assessed by the involved skin surface area,
• and/or 50% decrease or normalisation of biological markers of inflammation (either CRP, ESR or fibrin).

An independent adjudication committee blinded to the treatment received, will review primary endpoint for all patients based on clinical files and standardized photographs, to validate the response.

Other secondary criteria will be assessed. Overall, this study will require a molecular analysis done on patient's tissue, the final aim being to evaluate efficiency and tolerance of targeted treatments chosen in a personalized analysis when classification is impossible.

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Paris, France, 75014
    • Hôpital Cochin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients (men or women) aged 18 years old and over
• Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract, eye, nerves and brain tissues, respiratory tract, cardio-vascular disorders, genito-urinary tract including kidney, musculo-skeletal tissues. Skin involvement is mandatory in order to be able to compare involved and non-involved tissue
• Signed informed consent

The disease should be considered as non-classified despite classical and adapted investigations and evaluation through expert committee meeting.

The disease alters significantly quality of life. The impairment of quality of life will be assessed based on the investigator's assessment.

The disease has been resistant to at least two prior lines of treatment [for example : Hydroxychloroquine, Chloroquine, Colchicine, Methotrexate, Ciclosporine, Azathioprine, Mycophenolate mofetil, Disulone, Corticosteroids (prednisone, prednisolone, dexamethasone, methylprednisolone…)].

Exclusion Criteria:

• Patients presenting disease which is not featured by lesional and healthy skin areas, easy to biopsy
• Patients refusing biopsies
• Pregnancy
• Women of child-bearing potential unable to receive highly efficient contraception such as combined oral contraceptives, intra-uterine disposals, hormonal implants or the use of male condoms recommended in case of unstable or irregular partner or as a replacement method for transient unacessebility to hormonal method
• Breastfeeding
• Patients presenting disease needing urgent therapeutic measures
• Patients without health insurance or social security
• Participation in another interventional trial
• Patients under legal protection

• Patients unable to respect the wash out delay of previously taken medications before biopsy and before treatment initiation :

  • Hydroxychloroquine (wash out period = 30 days)
  • Chloroquine (wash out period = 7 days)
  • Colchicine (wash out period = 7 days)
  • Methotrexate (wash out period = 7 days)
  • Ciclosporine (wash out period = 14 days)
  • Azathioprine (wash out period = 14 days)
  • Mycophenolate mofetil (wash out period = 14 days)
  • Disulone (wash out period = 7 days)
  • Corticosteroids (=prednisone, prednisolone, dexamethasone, methylprednisolone) (wash out period = 7 days for doses greater than 5mg)
• Patients with contra-indications to treatments : Severe or active infections including tuberculosis

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Rituximab	Drug: Rituximab; 2 sessions of 1000 mg at inclusion and 15 days after inclusion
Experimental: Kineret	Drug: Kineret; 100 mg, once/day sc 6 months
Experimental: Humira	Drug: Humira; 40 mg/15 days sc 6 months
Experimental: Stelara	Drug: Stelara; 45 mg/12 weeks sc, 6 months
Experimental: Cosentyx	Drug: Cosentyx; 300mg sc every week for 1 month, then 300 mg/month sc for 5 months
Experimental: Roactemra	Drug: Roactemra; 480 mg/perf/4 weeks 6 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composite clinico-biological evaluation	Response will be assessed at month 6 with a composite endpoint defined as improvement of at least of 2 of the 3 following parameters: 50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10), where clinician will be asked the following question: "Please indicate, according to your clinical experience and taking into account all systemic manifestations, the level of disease activity in this patient using the following scale:"; and/or 50% improvement of cutaneous activity assessed by the involved skin surface area (according the rule of 9%). Standardised skin pictures will be done in order to centrally review cutaneous response.; and/or 50% decrease or normalisation of biological markers of inflammation (either CRP, ESR or fibrin)	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Infections	to evaluate tolerance	12 months
liver cell count toxicities	to evaluate tolerance	12 months
kidney cell count toxicities	to evaluate tolerance	12 months
blood cell count toxicities	to evaluate tolerance	12 months
Change in Physician Global Assessment (PGA)	to evaluate clinical efficiency	1 month,
Change in Physician Global Assessment (PGA)	to evaluate clinical efficiency	3 months,
Change in Physician Global Assessment (PGA)	to evaluate clinical efficiency	6 months,
Change in continuous PGA	to evaluate clinical efficiency	9 months
Change in continuous PGA	to evaluate clinical efficiency	12 months
Change in British Isles Lupus Assessment Group (BILAG)	to evaluate clinical efficiency	3 months
Change in British Isles Lupus Assessment Group (BILAG)	to evaluate clinical efficiency	6 months
Change in British Isles Lupus Assessment Group (BILAG)	to evaluate clinical efficiency	9 months
Change in British Isles Lupus Assessment Group (BILAG)	to evaluate clinical efficiency	12 months
Change in Systemic Lupus Erythematosus Responder Index (SRI)	to evaluate clinical efficiency	3 months
Change in Systemic Lupus Erythematosus Responder Index (SRI)	to evaluate clinical efficiency	6 months
Change in Systemic Lupus Erythematosus Responder Index (SRI)	to evaluate clinical efficiency	9 months
Change in Systemic Lupus Erythematosus Responder Index (SRI)	to evaluate clinical efficiency	12 months
Change in Cutaneous Lupus Disease Area and Severity Index (CLASI)	to evaluate clinical efficiency	3 months
Change in Cutaneous Lupus Disease Area and Severity Index (CLASI)	to evaluate clinical efficiency	6 months
Change in Cutaneous Lupus Disease Area and Severity Index (CLASI)	to evaluate clinical efficiency	9 months
Change in Cutaneous Lupus Disease Area and Severity Index (CLASI)	to evaluate clinical efficiency	12 months
Change in 36-Item Short Form Health Survey (SF36)	to evaluate clinical efficiency	3 months
Change in 36-Item Short Form Health Survey (SF36)	to evaluate clinical efficiency	6 months
Change in 36-Item Short Form Health Survey (SF36)	to evaluate clinical efficiency	9 months
Change in 36-Item Short Form Health Survey (SF36)	to evaluate clinical efficiency	12 months
Change in CRP	to evaluate biological efficiency	1 month
Change in CRP	to evaluate biological efficiency	3 months
Change in CRP	to evaluate biological efficiency	6 months
Change in CRP	to evaluate biological efficiency	9 months
Change in CRP	to evaluate biological efficiency	12 months
Change in ESR (Erythrocyte sedimentation rate)	to evaluate biological efficiency	1 month
Change in ESR (Erythrocyte sedimentation rate)	to evaluate biological efficiency	3 months
Change in ESR (Erythrocyte sedimentation rate)	to evaluate biological efficiency	6 months
Change in ESR (Erythrocyte sedimentation rate)	to evaluate biological efficiency	9 months
Change in ESR (Erythrocyte sedimentation rate)	to evaluate biological efficiency	12 months
Change in Fibrin	to evaluate biological efficiency	1 month,
Change in Fibrin	to evaluate biological efficiency	3 months
Change in Fibrin	to evaluate biological efficiency	6 months
Change in Fibrin	to evaluate biological efficiency	9 months
Change in Fibrin	to evaluate biological efficiency	12 months
Decreased in serum increased cytokines, in selected RNA in peripheral blood and skin specimens	to evaluate targeted biological efficiency	1 month
Decreased in serum increased cytokines, in selected RNA in peripheral blood and skin specimens	to evaluate targeted biological efficiency	3 months
Decreased in serum increased cytokines, in selected RNA in peripheral blood and skin specimens	to evaluate targeted biological efficiency	6 months
Decreased in serum increased cytokines, in selected RNA in peripheral blood and skin specimens	to evaluate targeted biological efficiency	12 months
RNA analysis of targeted cytokines and RNA sequencing		6 months

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborators: URC-CIC Paris Descartes Necker Cochin
• Investigators: Principal Investigator: Selim ARACTINGI, PhD, Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Actual): October 20, 2020
• Primary Completion (Actual): November 20, 2025
• Study Completion (Actual): November 20, 2025

Study Registration Dates

• First Submitted: June 25, 2018
• First Submitted That Met QC Criteria: August 27, 2018
• First Posted (Actual): August 29, 2018

Study Record Updates

• Last Update Posted (Actual): May 20, 2026
• Last Update Submitted That Met QC Criteria: May 18, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: skin; auto-immune diseases; auto-inflammatory diseases; Personalized treatment; Inflammatory diseases; Targeted treatments
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Intercellular Signaling Peptides and Proteins; Antibodies, Monoclonal, Murine-Derived; Cytokines; Adalimumab; Rituximab; Ustekinumab; Interleukin 1 Receptor Antagonist Protein; tocilizumab; secukinumab
• Other Study ID Numbers: P160906J; 2017-000519-18 (Registry Identifier: ID-RCB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No